KR102949437B1 - O-결합형 n-아세틸글루코사민화 단백질 유사 물질 및 이것을 함유하는 섬유증 치료약 - Google Patents

O-결합형 n-아세틸글루코사민화 단백질 유사 물질 및 이것을 함유하는 섬유증 치료약

Info

Publication number
KR102949437B1
KR102949437B1 KR1020227019780A KR20227019780A KR102949437B1 KR 102949437 B1 KR102949437 B1 KR 102949437B1 KR 1020227019780 A KR1020227019780 A KR 1020227019780A KR 20227019780 A KR20227019780 A KR 20227019780A KR 102949437 B1 KR102949437 B1 KR 102949437B1
Authority
KR
South Korea
Prior art keywords
acetylglucosamine
linked
protein analog
protein
unit
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020227019780A
Other languages
English (en)
Korean (ko)
Other versions
KR20220123383A (ko
Inventor
히로히코 이세
사오리 마츠오
Original Assignee
고쿠리쓰다이가쿠호진 규슈다이가쿠
소마아루 가부시끼가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 고쿠리쓰다이가쿠호진 규슈다이가쿠, 소마아루 가부시끼가이샤 filed Critical 고쿠리쓰다이가쿠호진 규슈다이가쿠
Publication of KR20220123383A publication Critical patent/KR20220123383A/ko
Application granted granted Critical
Publication of KR102949437B1 publication Critical patent/KR102949437B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0024—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid beta-D-Glucans; (beta-1,3)-D-Glucans, e.g. paramylon, coriolan, sclerotan, pachyman, callose, scleroglucan, schizophyllan, laminaran, lentinan or curdlan; (beta-1,6)-D-Glucans, e.g. pustulan; (beta-1,4)-D-Glucans; (beta-1,3)(beta-1,4)-D-Glucans, e.g. lichenan; Derivatives thereof
    • C08B37/0027—2-Acetamido-2-deoxy-beta-glucans; Derivatives thereof
    • C08B37/003—Chitin, i.e. 2-acetamido-2-deoxy-(beta-1,4)-D-glucan or N-acetyl-beta-1,4-D-glucosamine; Chitosan, i.e. deacetylated product of chitin or (beta-1,4)-D-glucosamine; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/26—Acyclic or carbocyclic radicals, substituted by hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A61K31/78—Polymers containing oxygen of acrylic acid or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F120/00—Homopolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and only one being terminated by only one carboxyl radical or a salt, anhydride, ester, amide, imide or nitrile thereof
    • C08F120/02—Monocarboxylic acids having less than ten carbon atoms; Derivatives thereof
    • C08F120/10—Esters
    • C08F120/34—Esters containing nitrogen, e.g. N,N-dimethylaminoethyl (meth)acrylate
    • C08F120/36—Esters containing nitrogen, e.g. N,N-dimethylaminoethyl (meth)acrylate containing oxygen in addition to the carboxy oxygen, e.g. 2-N-morpholinoethyl (meth)acrylate or 2-isocyanatoethyl (meth)acrylate

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Polymers & Plastics (AREA)
  • Materials Engineering (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
KR1020227019780A 2019-11-14 2020-11-13 O-결합형 n-아세틸글루코사민화 단백질 유사 물질 및 이것을 함유하는 섬유증 치료약 Active KR102949437B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2019206265 2019-11-14
JPJP-P-2019-206265 2019-11-14
PCT/JP2020/042362 WO2021095828A1 (ja) 2019-11-14 2020-11-13 Ｏ結合型ｎ－アセチルグルコサミン化タンパク質様物質及びこれを含有する線維症治療薬

Publications (2)

Publication Number Publication Date
KR20220123383A KR20220123383A (ko) 2022-09-06
KR102949437B1 true KR102949437B1 (ko) 2026-04-08

Family

ID=75912746

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227019780A Active KR102949437B1 (ko) 2019-11-14 2020-11-13 O-결합형 n-아세틸글루코사민화 단백질 유사 물질 및 이것을 함유하는 섬유증 치료약

Country Status (7)

Country Link
US (1) US20220389047A1 (https=)
EP (1) EP4059567A4 (https=)
JP (1) JP7637948B2 (https=)
KR (1) KR102949437B1 (https=)
CN (1) CN114945609A (https=)
CA (1) CA3158028A1 (https=)
WO (1) WO2021095828A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20250197865A1 (en) * 2022-03-03 2025-06-19 Kyushu University, National University Corporation Pharmaceutical composition for treatment or prevention of fibrotic disease
EP4603100A1 (en) * 2022-10-14 2025-08-20 Kyushu University, National University Corporation Antifibrotic agent, pharmaceutical composition for treating fibrosis, and method for inactivating myofibroblast
WO2025216313A1 (ja) * 2024-04-12 2025-10-16 国立大学法人九州大学 共重合体、抗線維化剤、線維症治療用医薬組成物及び筋線維芽細胞を不活性化する方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004099271A1 (ja) * 2003-05-08 2004-11-18 Toyo Boseki Kabushiki Kaisha 糖鎖含有水溶性ポリマー化合物

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7244830B2 (en) * 2001-01-12 2007-07-17 Emory University Glycopolymers and free radical polymerization methods
JP2004043782A (ja) * 2002-05-09 2004-02-12 Toyobo Co Ltd オリゴ糖合成用水溶性高分子プライマー
JP2007518830A (ja) * 2003-12-31 2007-07-12 カウンシル オブ サイエンティフィク アンド インダストリアル リサーチ Ｎ−セチルグルコサミンを含有するオリゴマー
JP2006276238A (ja) * 2005-03-28 2006-10-12 Fuji Photo Film Co Ltd 光重合性組成物及び平版印刷版原版
JP5044777B2 (ja) * 2006-05-09 2012-10-10 国立大学法人 東京医科歯科大学 細胞固定化基材被覆膜用材料
JP2011190257A (ja) 2010-02-22 2011-09-29 Oita Univ 組織線維化疾患の予防または治療剤
WO2012171035A1 (en) 2011-06-10 2012-12-13 University Of Washington Through Its Center For Commercialization Carbohydrate-based compositions and methods for targeted drug delivery
JP7109040B2 (ja) 2016-07-25 2022-07-29 国立大学法人金沢大学 線維化抑制剤
JP2019206265A (ja) 2018-05-29 2019-12-05 株式会社デンソー 車両用空調装置
JP7341031B2 (ja) * 2018-10-31 2023-09-08 ソマール株式会社 間葉系幹細胞の分離・選別方法、培養方法及びそれに用いる選別材料

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004099271A1 (ja) * 2003-05-08 2004-11-18 Toyo Boseki Kabushiki Kaisha 糖鎖含有水溶性ポリマー化合物

Also Published As

Publication number Publication date
JP7637948B2 (ja) 2025-03-03
KR20220123383A (ko) 2022-09-06
TW202131933A (zh) 2021-09-01
JPWO2021095828A1 (https=) 2021-05-20
US20220389047A1 (en) 2022-12-08
CN114945609A (zh) 2022-08-26
EP4059567A1 (en) 2022-09-21
CA3158028A1 (en) 2021-05-20
WO2021095828A1 (ja) 2021-05-20
EP4059567A4 (en) 2023-11-22

Similar Documents

Publication Publication Date Title
KR102949437B1 (ko) O-결합형 n-아세틸글루코사민화 단백질 유사 물질 및 이것을 함유하는 섬유증 치료약
EP1352061B9 (de) Verfahren zur hemmung der expression eine zielgens
US11473083B2 (en) Compositions and methods for decreasing tau expression
US20220143071A1 (en) Antisense-oligonucleotides as inhibitors of tgf-r signaling
US9127280B2 (en) Oligonucleotide, and therapeutic agent for dyslipidemia containing oligonucleotide as active ingredient
EA018986B1 (ru) Соединения-антагонисты рнк для модуляции активности бета-катенина
EA019939B1 (ru) МОДИФИЦИРОВАННЫЙ ОЛИГОМЕР ДЛЯ УМЕНЬШЕНИЯ КОЛИЧЕСТВА микроРНК В КЛЕТКЕ
Jasinski-Bergner et al. Adipokines regulate the expression of tumor-relevant MicroRNAs
Campbell et al. Targeting pro-invasive oncogenes with short chain fatty acid-hexosamine analogues inhibits the mobility of metastatic MDA-MB-231 breast cancer cells
Sedlar et al. Glycopolymer inhibitors of galectin-3 suppress the markers of tissue remodeling in pulmonary hypertension
TWI917337B (zh) 氧連結型n-乙醯葡萄糖胺化類蛋白物質、及含有該氧連結型n-乙醯葡萄糖胺化類蛋白物質之纖維化症治療藥
KR101409445B1 (ko) ＯＴＵＢ１ 발현을 저해하는 ｓｉＲＮＡ 및 이를 포함하는 약제학적 조성물
EP4603100A1 (en) Antifibrotic agent, pharmaceutical composition for treating fibrosis, and method for inactivating myofibroblast
CN111110666B (zh) 一种治疗消化道癌症的药物组合物
KR101215759B1 (ko) 오로소뮤코이드를 포함하는 조성물의 용도
US20180140681A1 (en) Composition for preventing or treating autoimmune disease, containing ssu72 as active ingredient
JP7840505B2 (ja) 変形性関節症及び／又は関節リウマチの予防及び／又は治療用医薬組成物
KR101596276B1 (ko) Ｓｉｒｔ７ 단백질의 탈아세틸화 활성을 저해하는 억제제를 유효성분으로 포함하는 암 예방 또는 치료용 약학 조성물
KR101547885B1 (ko) Ｓｉｒｔ７ 단백질의 탈아세틸화 활성을 저해하는 억제제를 유효성분으로 포함하는 암 예방 또는 치료용 약학 조성물
RU2833910C1 (ru) Средство на основе енаминогидразонотиазольного производного усниновой кислоты, обладающее способностью усиливать цитотоксическое, противоопухолевое и антиметастатическое действие топотекана
RU2809720C2 (ru) Применение производного инденофлуорена для ингибирования и/или элиминации опухолевых клеток
WO2025216313A1 (ja) 共重合体、抗線維化剤、線維症治療用医薬組成物及び筋線維芽細胞を不活性化する方法
RU2794975C2 (ru) Усовершенствованное соединение для лечения сердечной недостаточности
JP7089715B2 (ja) ヒアルロン酸合成阻害剤、およびヒアルロン酸が関与する疾患または状態の治療または予防剤
Zhang et al. Regulatory roles of mitochondrial ribosome in lung diseases and single cell biology

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D22-EXM-PE0701 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

Q13 Ip right document published

Free format text: ST27 STATUS EVENT CODE: A-4-4-Q10-Q13-NAP-PG1601 (AS PROVIDED BY THE NATIONAL OFFICE)